Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7872640 | 0.88 | OPRD1 (0.56) | MMP2OPRK1OPRD1OPRM1 | |
| SCHEMBL7872647 | 0.88 | OPRD1 (0.56) | MMP2OPRK1OPRD1OPRM1 | |
| SCHEMBL30977978 | 0.86 | OPRK1 (0.55) | MMP2OPRK1REN | |
| SCHEMBL30407529 | 0.85 | OPRK1 (0.56) | OPRK1OPRD1OPRM1 | |
| SCHEMBL30497071 | 0.85 | GNPAT (0.58) | OPRK1OPRD1OPRM1 | |
| SCHEMBL29868240 | 0.84 | OPRK1 (0.58) | MMP2OPRK1OPRD1OPRM1 | |
| SCHEMBL31528348 | 0.84 | ERAP2 (0.58) | MMP2OPRK1OPRD1OPRM1REN | |
| SCHEMBL29350734 | 0.84 | ERAP2 (0.58) | MMP2OPRK1OPRD1OPRM1REN | |
| SCHEMBL31181266 | 0.83 | GNPAT (0.59) | OPRK1OPRD1OPRM1 | |
| SCHEMBL1371636 | 0.83 | FURIN (0.49) | MMP2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | MMP2 284/4885OPRK1 3911/4885OPRD1 4036/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | MMP2 284/4885OPRK1 3911/4885OPRD1 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.